Reportlinker.com

Reportlinker.com

June 25, 2008 15:51 ET

Key Challenges and Issues facing the Blood Disorders Market Analysis and Forecasts Report to 2013

LONDON, UNITED KINGDOM--(Marketwire - June 25, 2008) - Reportlinker.com announces that a new market research report related to the Cardiovascular diseases industry is available in its catalogue.

Blood Disorders Market Analysis and Forecasts Report to 2013

http://www.reportlinker.com/p090280/Blood-Disorders-Market-Analysis-and-Forecasts-Report-to-2013.html

In 2007, blood diseases cost the US's economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. This brand new blood diseases treatments report breaks down therapies into four main groups:

Antithrombotics

- Anti-anaemics

- Clotting Factors

- Others

In 2006 visiongain valued this market at $37406m, But do you know how the blood diseases treatments market will fare 5, 10 and 15 years from now? Will it increase in sales and bring in significant profits or will it be rocked by widespread patent expiration and ensuing generic competition? This report provides these answers, with detailed quantitative and qualitative analysis. This is information every player in the blood diseases treatments market should not be without.

Visiongain's new Blood Disorders 2008 report covers:

- An in-depth analysis of the major blood diseases and treatments

- Discussion of most effective innovative treatments for blood diseases

- Trends in the overall world blood diseases treatments market, with detailed market forecasts from 2008 to 2023

- Reasons behind the trends

- A breakdown of the world market into the principal market segments, with forecasts and predictions of future market share values

- Sales forecasts of the leading drugs in each sub-market

- A SWOT analysis of the blood disorders market

- Discussion of relevant market drivers and restraints

- A geographical breakdown of relevant global sales trends into the leading national markets

- Pipeline developments in blood disorders

This study was achieved through research of relevant news, company reports, expert opinion, academic literature and gold-standard IMS databases. Financial forecasting based upon in-depth research was performed, with accompanying SWOT analyses. The result is a comprehensive market-based study with extensive analysis and informed opinion.

Why You Should Buy This Report

This 115+ page report features over 25 tables, 50 graphs, market forecasts, current news, detailed insight, the latest developments, all with up-to-date analysis and informed opinion. This visiongain report is a vital aid to your gaining an understanding of this important market sector, giving your company 'the edge' on its competitors.

Importantly report gives answers to relevant questions such as:

- How will sales for blood disorder treatments change from 2006-2013 and beyond?

- What is the market share of the four classes of treatments and how will they change in the years ahead?

- What are the top ten drugs in the blood diseases treatments market currently - how will they fare from now until 2013?

- Which group of treatments will contract the most over the next five years?

- Which drugs dominate each treatment group, present and future?

- What are the main issues facing the market worldwide, both present and up to 2023?

- Where will the main opportunities lie from now onwards?

- Will the US continue to dominate the blood diseases treatments market? Where do the other leading pharmaceutical nations stand?

- In which stages of development are relevant pipeline products and what are their prospects?

Other benefits to you when you order this report:

- Full searchable report when you buy the company or corporate editions

- Copies can be easily printed for offline reading

Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


Chapter 1: Executive Summary
Chapter 2: Blood Diseases and their Treatments
2.1 Functions of Blood


2.1.1 Haemopoiesis
2.1.2 Haemostasis

2.2 Anaemia


2.2.1 Iron Deficiency
2.2.2 Anaemia of Chronic Disease
2.2.3 Megaloblastic Anaemia
2.2.4 Pernicious Anaemia
2.2.5 Aplastic Anaemia
2.2.6 Haemolytic Anaemia


2.2.6.1 Inherited Haemolytic Anaemia: Hereditary Spherocytosis, Hereditary
 Elliptocytosis, Thalassaemia, Sickle Cell Disease and Glucose-6-phosphate
 Deficiency
2.2.6.2 Acquired Haemolytic Anaemia: Autoimmune Haemolytic Anaemia and
 Non-immune Haemolytic Anaemia

2.2.7 Anaemia and Aging

2.3 Myeloproliferative and Myelodysplastic Disorders


2.3.1 Polycythaemia: Polycythaemia Vera and Secondary Polycythaemia
2.3.2 Primary Thrombocythaemia
2.3.3 Primary Myelofibrosis (Myelosclerosis)

2.4 Bleeding Disorders


2.4.1 Autoimmune Thrombocytopenic Purpura
2.4.2 Inherited Coagulation Disorders


2.4.2.1 Haemophilia A
2.4.2.2 Haemophilia B
2.4.2.3 Von Willebrand's Disease

2.4.3 Acquired Coagulation Disorders


2.4.3.1 Disseminated Intravascular Coagulation

2.5 White Blood Cell Disorders


2.5.1 Neutropenia

2.6 Thrombosis


2.6.1 Arterial Thrombosis
2.6.2 Venous Thrombosis

Chapter 3: Blood Diseases Treatments
3.1 Antithrombotic Treatments


3.1.1 Platelet Aggregation Inhibitors
3.1.2 Anticoagulants Injectable
3.1.3 Anticoagulants Non-injectable
3.1.4 Fibrinolytics
3.1.5 Direct Thrombin Inhibitors
3.1.6 Antithrombin III and Other Protease Inhibitors
3.1.7 Other Antithrombotic Treatments

3.2 Anti-anaemic Treatments


3.2.1 Erythropoietin Products
3.2.2 Iron Replacement Therapy
3.2.3 Other Anti-anaemic Treatments

3.3 Clotting Factors
3.4 Other Treatments
Chapter 4: Blood Diseases Treatments World Market
4.1 Market Analysis
4.2 Market Shares
4.3 Top Ten Drugs
4.4 Percentage Change 2006-2013
Chapter 5: Antithrombotics Market
5.1 Market Analysis
5.2 The Platelet Aggregation Inhibitors Dominate the Antithrombotics Market
5.3 Drugs Generating below $300m dominate the Antithrombotics Market
5.4 Platelet Aggregation Inhibitors Market
5.5 Plavix Dominates the Platelet Aggregation Inhibitors Market
5.6 Plavix


5.6.1 Threat to Plavix's Sales in 2006
5.6.2 Plavix's Competitors
5.6.3 Plavix's Loss of Patent Protection

5.7 Clopidogrel Aptx's Withdrawal
5.8 Pletaal


5.8.1 Pletaal's Indications
5.8.2 Potential Market Expansion for Pletaal

5.9 Integrilin


5.9.1 The Leading Glycoprotein IIb/IIIa Receptor Inhibitor
5.9.2 Integrilin's Competitors
5.9.3 Potential Market Expansion for Integrilin

5.10 Injectable Anticoagulants Market
5.11 Lovenox Dominates the Injectable Anticoagulants Market
5.12 Lovenox


5.12.1 A Leading Low Molecular Weight Heparin
5.12.2 Lovenox's Loss of Patent Protection in 2012
5.12.3 Potential Market Expansion for Lovenox
5.12.4 Lovenox's Competitors

5.13 Fraxiparine
5.14 Fragmin
5.15 Other Anti-thrombotics
Chapter 6: Anti-anaemics World Market
6.1 Market Analysis
6.2 Erythropoietin Products Dominate the Anti-anaemics Market
6.3 Aranesp Dominates the Anti-anaemics Market
6.4 Erythropoietin Products
6.5 Aranesp Dominates the Erythropoietin Products Market
6.6 Aranesp


6.6.1 Fears over Erythropoietin Products Overuse
6.6.2 Scope for Expansion of Aranesp's Indications
6.6.3 Aranesp's Edge over Competitors
6.6.4 Other Competitiors of Aranesp
6.6.5 Entry of Erythropoietin Biosimilars in Europe

6.7 Erypo


6.7.1 Generic versions of Erypo

6.8 Epogen
6.9 NeoRecormon
6.10 Espo
6.11 Iron Replacement Therapy
6.12 Drugs with Revenues less than $300m Dominate the Iron Replacement
 Therapy Market
6.13 Venofer
6.14 Other Anti-Anaemics
Chapter 7: Clotting Factors Market
7.1 Market Analysis
7.2 Novoseven's Change in Market Share
7.3 NovoSeven
Chapter 8: Forces Affecting the Blood Diseases Treatments Market
8.1 SWOT Analysis of the Blood Diseases Treatments Market
8.2 Market Drivers
8.3 Market Restraints
8.4 Plavix and Parallel Trade
8.5 Strong developmental Pipeline for Drugs on Parr with Lovenox
8.6 Ongoing Fears Over the use of Erythropoietin Products in Cancer Patients
8.7 FDA Approves New Haemophilia Treatment
Chapter 9: Geographical Breakdown of the Blood Diseases Treatments Market
9.1 The US Holds over 50% Market Share of the Blood Diseases Treatments
 Market
9.2 Increasing Market Share of Developing Countries at the Cost of Developed
 Countries
Chapter 10: Pipeline Products
10.1 Anti-thrombotics in the Pipeline
10.2 Anti-Anaemics in the Pipeline
10.3 Clotting Factors in the Pipeline
10.4 Other Blood Diseases Treatments in the Pipeline
Chapter 11: Conclusion
11.1 Blood Diseases and Treatments
11.2 Blood Diseases Treatments World Market
11.3 Blood Diseases Treatments Market Segments
11.4 Issues and Opportunities
11.5 Products in Development
11.6 Geographical Breakdown of the Market
11.7 Afterword
List of Tables
Table 4.1: Forecasts for Blood Diseases Treatments, 2006-2013
Table 4.2: Forecasts for Blood Diseases Treatments 2018 and 2023
Table 4.3: Top Ten Products in the Blood Diseases Treatment World Market
 2006
Table 5.1: Antithrombotics Market Forecast, 2006-2013
Table 5.2: Forecasts for Platelet Aggregation Inhibitors, 2006-2013
Table 5.3: Forecasts for Platelet Aggregation Inhibitors, 2018 and 2023
Table 5.4: Injectable Anticoagulants Market Forecast, 2006-2013
Table 5.5: Injectable Anticoagulants Market Forecast, 2018 and 2023
Table 6.1: Anti-anaemics Market Forecast, 2006-2013
Table 6.2: Anti-anaemics Market Forecast, 2018 and 2023
Table 6.3: Forecasts for Erythropoietin Products, 2006-2013
Table 6.4: Forecasts for Erythropoietin Products, 2018 and 2023
Table 6.5: Forecasts for Iron Replacement Therapy, 2006-2013
Table 6.6: Forecasts for Iron Replacement Therapy, 2018 and 2023
Table 7.1: Forecasts for Clotting Factors, 2006-2013
Table 7.2: Forecasts for Clotting Factors, 2018 and 2023
Table 8.1: A SWOT Chart for the Blood Diseases Treatments Market, 2006-2013
Table 9.1: Revenue and Market Share of the Leading Pharmaceutical Markets,
 2006 and 2013
Table 10.1: Platelet Aggregation Inhibitors in Development, 2008
Table 10.2: Injectable Anticoagulants in Development, 2008
Table 10.3: Other Antithrombotics in Development, 2008
Table 10.4: Erythropoietin Products in Development, 2008
Table 10.5: Other Anti-anaemics in Development, 2008 
Table 10.6: Clotting Factors in Development, 2008
Table 10.7: Other Blood Diseases Treatments in Development, 2008
Table 11.1: Forecasts for Blood Diseases Treatments, 2006-2013
List of Figures
Figure 4.1: Forecasts for Blood Diseases Treatments by Market Segment,
 2006-2013
Figure 4.2: Blood Diseases Treatments World Market Forecast, 2006-2013
Figure 4.3: Blood Diseases Treatments Market Share, 2006
Figure 4.4: Blood Diseases Treatments Market Share, 2013
Figure 4.5: Changes in Market Share of the Market Segments
Figure 4.6: Market Share of the Main Drugs, 2006
Figure 4.7: Market Share of the Main Drugs, 2013
Figure 4.8: Changes in revenue from 2006 to 2013 by Market Segment
Figure 5.1: Antithrombotics Market Forecast, 2006-2013
Figure 5.2: Antithrombotics Market Share, 2006
Figure 5.3: Antithrombotics Market Share, 2013
Figure 5.4: Market Share of the Main Antithrombotics, 2006
Figure 5.5: Market Share of the Main Antithrombotics, 2013
Figure 5.6: Forecasts for Platelet Aggregation Inhibitors, 2006-2013
Figure 5.7: Platelet Aggregation Inhibitors Market Forecast, 2006-2013
Figure 5.8: Market Share of Platelet Aggregation Inhibitors, 2006
Figure 5.9: Market Share of Platelet Aggregation Inhibitors, 2013
Figure 5.10: Plavix Forecast, 2006-2013
Figure 5.11: Clopidogrel Aptx Forecast, 2006-2013
Figure 5.12: Pletaal Forecast, 2006-2013
Figure 5.13: Integrilin Forecast, 2006-2013
Figure 5.14: Forecasts for Injectable Anticoagulants, 2006-2013
Figure 5.15: Injectable Anticoagulants Market Forecast, 2006-2013
Figure 5.16: Injectable Anticoagulants Market Share, 2006
Figure 5.17: Injectable Anticoagulants Market Share, 2013
Figure 5.18: Lovenox Forecast, 2006-2013
Figure 5.19: Fraxiparine Forecast, 2006-2013 
Figure 5.20: Fragmin Forecast, 2006-2013
Figure 6.1: Anti-anaemics Market Forecast, 2006-2013
Figure 6.2: Anti-anaemics Market Share, 2006-2013
Figure 6.3: Anti-anaemics Market Share, 2006-2013
Figure 6.4: Market Share of the Main Anti-anaemics, 2006
Figure 6.5: Market Share of the Main Anti-anaemics, 2013
Figure 6.6: Forecasts for Erythropoietin Products, 2006-2013
Figure 6.7: Erythropoietin Products Market Forecast, 2006-2013
Figure 6.8: Erythropoietin Products Market Share, 2006
Figure 6.9: Erythropoietin Products Market Share, 2013
Figure 6.10: Aranesp Forecast, 2006-2013
Figure 6.11: Erypo Forecast, 2006-2013
Figure 6.12: Epogen Forecast, 2006-2013
Figure 6.13: NeoRecormon Forecast, 2006-2013
Figure 6.14: Espo Forecast, 2006-2013
Figure 6.15: Forecasts for Iron Replacement Therapy, 2006-2013
Figure 6.16: Iron Replacement Therapy Market Forecast, 2006-2013
Figure 6.17: Iron Replacement Therapy, 2006
Figure 6.18: Iron Replacement Therapy Market Share 2013
Figure 6.19: Venofer Forecast, 2006-2013
Figure 7.1: Forecasts for Clotting Factors, 2006-2013
Figure 7.2: Clotting Factors Market Forecast, 2006-2013
Figure 7.3: Clotting Factors Market Share, 2006
Figure 7.4: Clotting Factors Market Share, 2013
Figure 7.5: NovoSeven Forecast, 2006-2013
Figure 9.1: Revenue of the Leading Pharmaceutical Markets, 2006 and 2013
Figure 9.2: Market Share of the Leading Pharmaceutical Markets, 2006 and
 2013
Figure 11.1: Blood Diseases Treatments World Market Forecast, 2006-2013
Figure 11.2: Market Share of the Main Drugs, 2006
Figure 11.3: Market Share of the Main Drugs, 2013
Figure 11.4: Changes in revenue from 2006 to 2013 by Market Segment
Figure 11.5: Forecasts for Blood Diseases Treatments by Market Segment,
 2006-2013
Figure 11.6: Market Share of the Leading Pharmaceutical Markets, 2006 and
 2013


More Details


Organisations Mentioned in this Report
Advancell
Affymax
Akzo Nobel
AMAG
Amgen
Apotex
Artisan
Asahi Kasei
AstraZeneca
Barcelona University
Barr
Baxter International
Bayer
Berlex
Boehringer Ingelheim
Bristol-Myers Squibb
Cogentus
Daiichi Sankyo
Eli Lilly
Emisphere
Flamel Technologies
Fuso
GlaxoSmithKline
Green Cross Corporation
Hexal
Hospira
Human Genome Sciences
JCR Pharmaceuticals
Johnson & Johnson
Kissei
Ligand
Lundbeck
Medicines Company
MedImmune
Menarini
National Cancer Institute
National Institutes of Health
Nektar
Novartis
Novo Nordisk
Nuvelo
Ono 
Ormont
Ortho-McNeil
Otsuka
Ovation Pharmaceuticals
PAION
PeriCor
Pfizer
Protherics
RHEI
Roche
sanofi-aventis
Schering-Plough
Servier
Snow Brand Milk Products
Stada
Takeda
Taro
Torii
Ube
Watson
Wyeth

To order this report:

Blood Disorders Market Analysis and Forecasts Report to 2013

http://www.reportlinker.com/p090280/Blood-Disorders-Market-Analysis-and-Forecasts-Report-to-2013.html

More market research reports here!

Contact Information